U.S. Cardiac Resynchronization Therapy Market Thumbnail Image

2021

U.S. Cardiac Resynchronization Therapy Market

U.S. Cardiac Resynchronization Therapy Market Size, Share, Competitive Landscape and Trend Analysis Report by Type, Application and End User : Opportunity Analysis and Industry Forecast, 2020-2027

LS : Medical Devices & Supplies

Select an option
Author's: Kishor Sherkar and Sumitra Choudhary | Roshan Deshmukh
Publish Date:

Get Sample to Email

The U.S. cardiac resynchronization therapy market size was valued at $965.6 million in 2019, and is projected to reach $983.3 million by 2027, registering a CAGR of 4.9% from 2020 to 2027.

Cardiac resynchronization therapy (CRT) is a treatment to assist heart beat with the right rhythm. It uses a pacemaker to restore the normal timing pattern of the heartbeat. CRT is a procedure to implant a device in the chest to make patient's heart's chambers squeeze (contract) efficiently. Cardiac resynchronization therapy is traditionally a treatment for patients who experience heart failure and then develop an arrhythmia. Cardiac resynchronization therapy finds applications in the intraventricular dyssynchrony, interventricular dyssynchrony, and atrioventricular dyssynchrony.

U.S.-Cardiac-Resynchronization-Therapy-Market-2020-2027

Factors that drive the growth of the CRT market include surge in elderly population, rise in prevalence of cardiovascular diseases (CVDs), increase in technological advances in the CRT pacemakers and CRT defibrillators, and surge in healthcare expenditure in the U.S. For instance, as per the statistics published by Centers for Disease Control and Prevention (CDC), about 6.2 million adults in the U.S. have heart failure. One patient dies every 36 seconds in the U.S. from cardiovascular disease. Heart disease is the leading cause of death for men, women, and individuals of most racial and ethnic groups in the country. Furthermore, around 655,000 Americans die from heart disease each year, which is one in every four deaths.

On the contrary, high cost of CRT therapy as well as the presence of stringent regulations for CRT devices in the U.S. are anticipated to restrain the U.S. cardiac resynchronization therapy market growth during the forecast period.

U.s. Cardiac Resynchronization Therapy Market Segmentation

The U.S. cardiac resynchronization therapy market is categorized into type, application, and end user. On the basis of type, the market is segmented into CRT pacemaker and CRT defibrillator. CRT pacemaker was introduced first within the healthcare industry in 1994. Pacemaker is a small electronic device, implanted below the collarbone and are connected to the heart through wires (leads) to the right chambers of the heart. The CRT defibrillator segment led the market in 2019, and is expected to continue this trend throughout the forecast period attributed to an increase in adoption of CRT defibrillators over CRT pacemakers as well as the launch of technologically advanced CRT defibrillators.

On the basis of application, the U.S. cardiac resynchronization therapy market is classified into intraventricular dyssynchrony, interventricular dyssynchrony, and atrioventricular dyssynchrony. Interventricular dyssynchrony refers to the discordance between the times of right ventricular (RV) and left ventricular (LV) contraction, or delay in segmental wall motion. Intraventricular dyssynchrony is the principal factor responsible for contractile dysfunction, the one most affected by and most predictive of response to resynchronization therapy. The intraventricular dyssynchrony segment spearheaded the market in 2019 in terms of revenue attributed to comparatively higher incidence of intraventricular dyssynchrony among patients with heart failure and left bundle branch block.

U.S. Cardiac Resynchronization Therapy Market
By Type
Your browser does not support the canvas element.

The CRT Defibrillator segment is expected to dominate the market throughout the forecast period.

On the basis of end user, the U.S. cardiac resynchronization therapy market is classified into hospitals, ambulatory surgical centers, and specialized cardiac treatment centers. Being the primary point for diagnosis and treatment of cardiovascular disease coupled with rise in adoption of cardiac resynchronization therapy devices in the hospital settings, the hospital segment is anticipated to witness supremacy throughout the review period.

U.S. Cardiac Resynchronization Therapy Market
By End User
Your browser does not support the canvas element.

The Hospitals segment held a substantial revenue share in 2019 and the specialized cardiac treatment centers segment will represent the fastest market growth over the forecast period.

The cardiac resynchronization therapy market is highly competitive in nature, as major players in this vertical are concentrating on growth strategies such as product launches, mergers and acquisitions (M&As), partnerships and collaborations to gain competitive advantage. For instance, in January 2020, Medtronic plc received CE Mark (Europe) for its Cobalt and Crome portfolio of implantable cardioverter-defibrillators (ICD) and cardiac resynchronization therapy-defibrillators (CRT-D). ICDs monitor heart rhythms and deliver therapy to correct heart rates that are too fast and can lead to sudden cardiac arrest. Cobalt and Crome heart devices deliver the opportunity of a personalized approach to defibrillator therapy. In addition, in July 2020, the U.S. Food and Drug Administration (USFDA) has approved Abbott's next-generation Gallant implantable cardioverter defibrillator and cardiac resynchronization therapy defibrillator devices in the U.S. These devices provide efficient battery longevity and MRI compatibility. In addition, the new devices offer Bluetooth technology and a new patient smartphone app for improved remote monitoring, allowing for increased patient/physician engagement and streamlined communications.

The key players operating in the U.S. cardiac resynchronization therapy market include Medtronic plc, Abbott Laboratories, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, Lepu Medical Technology (Beijing) Co., Ltd., LivaNova PLC, MEDICO S.p.A., MicroPort Scientific Corporation, OSCOR Inc., and Osypka Medical GmbH.

Key Benefits For Stakeholders

  • The study provides an in-depth analysis of the U.S. cardiac resynchronization therapy market size along with the current trends and future estimations to elucidate the imminent investment pockets
  • It offers market analysis from 2020 to 2027, which is expected to enable stakeholders to capitalize on the prevailing opportunities in the U.S. cardiac resynchronization therapy market
  • A comprehensive analysis on country assists to understand the country market and facilitate the strategic business planning and determine prevailing opportunities
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the U.S. cardiac resynchronization therapy market growth

U.S. Cardiac Resynchronization Therapy Market Report Highlights

Aspects Details
icon_5
By Type
  • CRT Pacemaker
  • CRT Defibrillator
icon_6
By Application
  • Intraventricular Dyssynchrony
  • Interventricular Dyssynchrony
  • Atrioventricular Dyssynchrony
icon_7
By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialized cardiac treatment centers
icon_8
Key Market Players

OSYPKA MEDICAL GmbH, LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD., MICROPORT SCIENTIFIC CORPORATION, BOSTON SCIENTIFIC CORPORATION, BIOTRONIK SE & CO. KG, ABBOTT LABORATORIES, MEDICO S.P.A., OSCOR INC., LIVANOVA PLC, MEDTRONIC PLC

Analyst Review

The U.S. cardiac resynchronization therapy market is expected to showcase profitable growth in the future. The market growth is characterized by factors such as growth in aging population, rise in sedentary lifestyle, surge in prevalence of cardiovascular diseases (CVDs), increase in technological developments in the CRT pacemakers and CRT defibrillators, the presence of advanced healthcare infrastructure, and surge in healthcare expenditure in the U.S.

As per the analysis in the report, the CRT defibrillator segment will be the highest contributor in the market throughout the forecast period pertaining to an increase in adoption of CRT defibrillators over CRT pacemakers as well as the launch of technologically advanced CRT defibrillators.

On the contrary, high cost of CRT therapy as well as the presence of stringent regulations for CRT devices in the U.S. are anticipated to restrict the market growth during the forecast period. The initial cost of cardiac resynchronization therapy pacemaker (CRT-P) is $16,218.44 and of cardiac resynchronization therapy defibrillator (CRT-D) is $36,263.73. Thus, this high cost of CRT therapy is anticipated to limit the market growth during the forecast period.

Author Name(s) : Kishor Sherkar and Sumitra Choudhary | Roshan Deshmukh
Frequently Asked Questions?

A surge in elderly population coupled with rise in prevalence of cardiovascular diseases (CVDs) will drive the market over the near future according to the KOLs.

The market has drawn the interest of the healthcare industry, owing to increase in technological advances in the CRT pacemakers and CRT defibrillators, and surge in healthcare expenditure in the U.S.

By type, the CRT defibrillator segment holds the maximum market share.

Cardiac resynchronization therapy is traditionally a treatment for patients who experience symptoms of heart failure and arrhythmia.

Cardiac resynchronization therapy is a treatment to help the heart beat with the right rhythm.

The total value of the U.S. cardiac resynchronization therapy market was $965.6 million in 2019.

The forecast period in the report is from 2020-2027.

The market value of cardiac resynchronization therapy market in 2027 is expected to reach $983.3 million.

The base year calculated in the report is 2019.

Loading Table Of Content...

U.S. Cardiac Resynchronization Therapy Market

Opportunity Analysis and Industry Forecast, 2020-2027